Table 1. Approved enzyme replacement therapies available for the lysosomal storage disorders .

LSDs	Deficient enzyme	Inheritance	FDA approved ERT and Brand name
MPS I (Hurler syn.) MPS II (Hunter syn.) MPS IV A (Morquio A syn.) MPS VI (Marateaux-Lamy syn.)	α-L-iduronidase Iduronate sulfatase N-acetylgalactosamine 6-sulfatase N-acetylgalactosamine 4-sulfatase	Autosomal X-linked Autosomal Autosomal	Laronidase (Aldurazyme™)/ 2003-FDA, EMA Idursulfase (Elaprase™)/ 2006-FDA; 2007-EMA Elosulfase Alfa (Vimzim™)/ 2014-FDA Galsulfase (Naglazyme™)/ 2005-FDA; 2006-EMA
Fabry disease	α-galactosidase	X-linked	Agalsidase α (Fabrazyme™)/ 2001-EMA Agalsidase β (Replagal™)/ 2003-FDA, EMA
Pompe diseas	α-glucosidase	Autosomal	Aglucosidase (Myozyme™)/ 2006-FDA, EMA Aglucosidase (Lumizyme™)/ 2010-FDA
Gaucher disease	β -glucocerebrosidase	Autosomal	Aglucerase (Ceredase™)/ 1991-FDA Imiglucerase (Cerezyme™)/ 1994-FDA; 1997-EMA Velaglucerase (VPRIV™)/ 2010-FDA, EMA Taliglucerase (Elelyso™)/ 2012-FDA
Lysosomal acid lipase deficiency	Lysosomal acid lipase	Autosomal	Sebelipase α (Kanuma™)/ 2015-FDA,EMA

MPS: mucopolysaccharidosis; FDA: U.S. Food and Drug Administration; EMA: European Medical Agency.^1,5,7